Instructors:
Michael Greicius, MD
Assistant Professor, Department of Neurology & Neurological Sciences
Hank Greely, JD
Professor, Stanford Law School
Learning Objectives
Gain understanding of clinical utility of personal genomic testing
Understand the regulatory structure governing genetic tests
Understand the (somewhat limited) risks of genetic discrimination
Understand the challenges from future clinical use of whole genome sequencing (or similarly informative technologies)
Announcements
Slides
Readings
1.
Roses AD. An inherited variable poly-T repeat genotype in TOMM40 in Alzheimer Disease. Arch. Neurol. 2008 67(5):536-41.
2.
Hogarth et al. The Current Landscape for Direct-to-Consumer Genetic Testing: Legal, Ethical, and Policy Issues, Annu. Rev. Genomics Hum. Genet. 2008. 9:161-82.
3.
Daniel Vorhaus, What Five FDA Letters Mean for the Future of DTC Genetic Testing, Genomics Law Report, posted June 11, 2010.
4.
Greely HT. Banning Genetic Discrimination, New Eng. J. Med. 2005;353:865-67.
5.
Ormond et al. Challenges in the Clinical Application of Whole-Genome Sequencing, Lancet 2010 May 15;375:1749-51.